(ii) WYJYD improves the levels of serum indicators (5-HT, BDNF, and NE) and the expressions of hippocampal tissue indicators (FGF2, FOXG1, and p-AKT/AKT) in the rat model of depression. Here, AKT1 is linked to depressive disorder.